Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ANIP Ani Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ANIP
Price (delayed)
$59.99
Market cap
$1.3B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$1.77B
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers),
Highlights
Ani Pharmaceuticals's revenue has increased by 30% YoY and by 10% from the previous quarter
The gross profit has grown by 23% year-on-year and by 10% since the previous quarter
The company's equity fell by 7% YoY but it rose by 3.7% QoQ
The company's EPS has shrunk by 178% YoY and by 21% QoQ
Ani Pharmaceuticals's net income has shrunk by 159% YoY and by 14% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com/
Key stats
What are the main financial stats of ANIP
Market
Valuations
Earnings
Shares outstanding
21.66M
Market cap
$1.3B
Enterprise value
$1.77B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.12
Price to sales (P/S)
1.78
EV/EBIT
N/A
EV/EBITDA
25.89
EV/Sales
2.63
Revenue
$674.07M
Gross profit
$399.98M
Operating income
-$10.37M
Net income
-$21.05M
EBIT
-$9.07M
EBITDA
$68.47M
Free cash flow
$66.61M
Per share
Balance sheet
Liquidity
EPS
-$1.26
EPS diluted
-$1.27
Free cash flow per share
$3.32
Book value per share
$19.23
Revenue per share
$33.63
TBVPS
$34.58
Total assets
$1.29B
Total liabilities
$848.96M
Debt
$622.82M
Equity
$418.62M
Working capital
$334.48M
Debt to equity
1.49
Current ratio
2.66
Quick ratio
1.86
Net debt/EBITDA
6.91
Margins
Efficiency
Dividend
EBITDA margin
10.2%
Gross margin
59.3%
Net margin
-3.1%
Operating margin
-1.5%
Return on assets
-1.9%
Return on equity
-5.4%
Return on invested capital
-1%
Return on capital employed
-0.8%
Return on sales
-1.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIP stock price
How has the Ani Pharmaceuticals stock price performed over time
Intraday
0.77%
1 week
-9.52%
1 month
-13.31%
1 year
-5.93%
YTD
8.52%
QTD
-10.4%
Financial performance
How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$674.07M
Gross profit
$399.98M
Operating income
-$10.37M
Net income
-$21.05M
Gross margin
59.3%
Net margin
-3.1%
Ani Pharmaceuticals's net income has shrunk by 159% YoY and by 14% QoQ
The company's operating income has shrunk by 155% QoQ and by 118% YoY
The net margin has shrunk by 145% YoY and by 3.3% QoQ
ANIP's operating margin has dropped by 114% since the previous quarter and by 113% year-on-year
Price vs fundamentals
How does ANIP's price correlate with its fundamentals
Growth
What is Ani Pharmaceuticals's growth rate over time
Valuation
What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.12
P/S
1.78
EV/EBIT
N/A
EV/EBITDA
25.89
EV/Sales
2.63
The company's EPS has shrunk by 178% YoY and by 21% QoQ
The P/B is 36% above the 5-year quarterly average of 2.3
The company's equity fell by 7% YoY but it rose by 3.7% QoQ
Ani Pharmaceuticals's revenue has increased by 30% YoY and by 10% from the previous quarter
The price to sales (P/S) is 15% lower than the 5-year quarterly average of 2.1 and 11% lower than the last 4 quarters average of 2.0
Efficiency
How efficient is Ani Pharmaceuticals business performance
The return on equity has dropped by 168% year-on-year and by 15% since the previous quarter
The ROA has plunged by 150% YoY and by 6% from the previous quarter
The company's return on sales has shrunk by 110% YoY and by 63% QoQ
Ani Pharmaceuticals's ROIC has plunged by 109% YoY and by 67% from the previous quarter
Dividends
What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIP.
Financial health
How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 52% more than its total liabilities
ANIP's total liabilities has surged by 94% year-on-year
Ani Pharmaceuticals's total assets has increased by 41% YoY
The debt is 49% higher than the equity
The debt to equity has soared by 137% YoY but it has decreased by 3.9% from the previous quarter
The debt has soared by 118% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.